Title:
CRYSTALLINE FORM OF FLUVATINIB OR FLUVATINIB METHANESULFONATE AND PREPARATION METHOD THEREFOR
Document Type and Number:
WIPO Patent Application WO/2021/143954
Kind Code:
A2
Abstract:
Disclosed in the present invention is a crystalline form of fluvatinib or fluvatinib methanesulfonate, and a preparation method therefor. The crystalline form I of the fluvatinib has characteristic diffraction peaks as shown in FIG. 1. The crystalline form of the fluvatinib methanesulfonate may take multiple forms, including seven crystalline forms, forms I-VII, wherein crystalline form III has characteristic diffraction peaks as shown in FIG. 9. Said crystalline forms are suited to manufacturing processes for fluvatinib methanesulfonate formulations.
More Like This:
| JP2521841 | [Title of Invention] Inhibitor of Retrovirus Protease |
| JPWO2020071550 | CDK8 inhibitors and their uses |
| JPH07179417 | HIV-PROTEASE INHIBITOR USEFUL FOR TREATMENT OF AIDS |
Inventors:
HE SHUAI (CN)
ZHANG YANG (CN)
LIU QIANG (CN)
CHEN ZHENGXIA (CN)
DAI MEIBI (CN)
FAN BIN (CN)
XIE PEIYU (CN)
ZHANG YANG (CN)
LIU QIANG (CN)
CHEN ZHENGXIA (CN)
DAI MEIBI (CN)
FAN BIN (CN)
XIE PEIYU (CN)
Application Number:
PCT/CN2021/081023
Publication Date:
July 22, 2021
Filing Date:
March 16, 2021
Export Citation:
Assignee:
CHONGQING PHARMACEUTICAL RES INSTITUTE CO LTD (CN)
YAOPHARMA CO LTD (CN)
YAOPHARMA CO LTD (CN)
International Classes:
C07D215/48; A61K31/47; A61P35/00; C07C303/32; C07C303/44
Foreign References:
| CN202010063033A | 2020-01-19 | |||
| CN109134365A | 2019-01-04 |
Attorney, Agent or Firm:
UNITALEN ATTORNEYS AT LAW (CN)
Download PDF: